Your session is about to expire
← Back to Search
Pre-Surgery Radiation Boost for Breast Cancer
N/A
Recruiting
Led By Bruce G Haffty
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured 1-5 weeks prior to surgery and measured 1-7 weeks after surgery
Awards & highlights
Study Summary
This trial is testing whether delivering a part of the radiation treatment before surgery, when doctors can still visualize the tumor, may help to better target the tumor and decrease the volume of normal irradiated tissue.
Who is the study for?
This trial is for individuals with non-metastatic breast cancer, who are in good physical condition (ECOG 0-1), and have no signs of cancer spread. Pregnant women must test negative for pregnancy. Participants should be willing to follow the study protocol and haven't had prior chest radiation or chemotherapy.Check my eligibility
What is being tested?
The trial studies the safety of a 'boost' dose of radiation given before surgery to target tumors more precisely, potentially improving cosmetic outcomes and tumor control. It includes quality-of-life assessments and MRI scans as part of evaluating this approach.See study design
What are the potential side effects?
Potential side effects may include skin changes, fatigue, discomfort at the treatment site, swelling or scar tissue formation in the treated breast area. The boost aims to minimize normal tissue exposure but individual reactions can vary.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ measured 1-5 weeks prior to surgery and measured 1-7 weeks after surgery
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured 1-5 weeks prior to surgery and measured 1-7 weeks after surgery
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in wound status from baseline every 3-6 months after WBI to access incidence of grade 3 or more wound complications after breast conserving surgery.
Secondary outcome measures
Physician reported cosmesis
Other outcome measures
Acute and late radiation toxicity
Clinical target volume (CTV)
Patient reported cosmesis
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (radiation therapy boost, WBI)Experimental Treatment6 Interventions
Prior to surgery, patients undergo radiation therapy boost over 4 fractions. Patients then undergo standard of care surgery 1-3 weeks from the last day of boost. 3 to 5 weeks after surgery, patients continue standard of care WBI in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Whole Breast Irradiation
2017
N/A
~160
Find a Location
Who is running the clinical trial?
Rutgers, The State University of New JerseyLead Sponsor
429 Previous Clinical Trials
64,177 Total Patients Enrolled
16 Trials studying Breast Cancer
1,910 Patients Enrolled for Breast Cancer
National Cancer Institute (NCI)NIH
13,657 Previous Clinical Trials
40,933,612 Total Patients Enrolled
940 Trials studying Breast Cancer
1,543,360 Patients Enrolled for Breast Cancer
Bruce G HafftyPrincipal InvestigatorRutgers Cancer Institute of New Jersey
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You require chemotherapy before surgery.You have received radiation therapy on the same side of your body as the breast or chest area.You have inflammatory breast cancer at an advanced stage.You can participate if you have cancer in both sides of your body at the same time.You are able to perform daily activities and take care of yourself with little to no assistance.You must have a negative pregnancy test within one month before receiving radiation therapy.You have breast cancer confirmed by a biopsy.You cannot have a baseline MRI for medical reasons.You do not have any visible signs of cancer in your lymph nodes during a physical exam or on imaging tests.You have multiple tumors in different places in your body.Cancer has spread to other parts of the body.You have another type of cancer at the same time, except for cancer in both breasts.You have a condition that makes receiving radiation therapy unsafe, like scleroderma or another collagen vascular disease.You do not have cancer that has spread to other parts of your body.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment (radiation therapy boost, WBI)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many volunteers are currently being enrolled in this clinical experiment?
"Indeed, clinicaltrials.gov provides evidence that this medical experiment is currently seeking participants. The trial was first made public on May 18th 2021 and its information has since been updated on July 27th 2022. 55 test subjects are needed across 4 different sites."
Answered by AI
Are any new participants being accepted into this clinical investigation?
"Affirmative. According to clinicaltrials.gov, this study is actively recruiting patients as of today's date; it was initially posted on May 18th 2021 and last updated on July 27th 2022. It requires 55 participants across 4 trial sites."
Answered by AI
How many sites within this state are actively conducting the trial?
"Enrolment for this trial is taking place at 4 different sites, including Rutgers New jersey Medical School in Newark, the Rutgers Cancer Institute of New Jersey in New Brunswick and Robert Wood Johnson University Hospital Somerset in Somerville. Additionally, there are numerous other locations that are currently recruiting patients."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger